Selected for the Japan Patent Office's IP Acceleration Program 'IPAS2022'
Epistra Inc. has been selected as a supported company in IPAS (IP Acceleration Program for Startups), implemented by the Japan Patent Office. Through this program, we will further accelerate our efforts in the intellectual property domain.
About IPAS
This program supports startups in building IP strategies to accelerate their growth. For startups founded on innovative technologies and ideas, intellectual property is a primary asset and a source of competitive advantage.
It is important for startups to build an “IP strategy” that enables strategic utilization of intellectual property for growth, including policies on patent filing and trade secret protection, as well as policies regarding collaboration and licensing with other companies.
However, many startups lack knowledge and expertise in intellectual property, or find themselves short on resources to develop IP strategies and acquire rights due to their focus on launching the business.
In this program, an “IP Mentoring Team” is organized, consisting of business experts and IP experts with the knowledge and skills to address each participating company’s challenges and support needs. Through approximately 5 months of mentoring alongside the IP Mentoring Team, participating companies diagnose and refine their business strategies and build IP strategies aligned with them. This strongly supports startups in strategically leveraging intellectual property to accelerate growth without losing competitiveness.
Related Articles
Epistra Contributes Article on "AI-Robot-Driven Drug Development" to Pharmacia, Journal of the Pharmaceutical Society of Japan
Epistra CTO Taku Tsuzuki and CEO Yosuke Ozawa contributed an article on AI-robot-driven drug development to Pharmacia, Vol. 62 No. 7, published by the Pharmaceutical Society of Japan.
Cell Culture Optimization Software 'CellTune Ver.2' Launches Globally
Epistra Inc. announces the global launch of 'CellTune Ver.2,' the updated version of the co-developed cell culture optimization software with Shimadzu Corporation, on June 29, 2026. The new version introduces cloud-based subscription delivery and overseas expansion of custom media manufacturing services.
Speaking Engagement: CEO Yosuke Ozawa Presented at the 10th Shonan iPark Regenerative Medicine Seminar
On June 3, 2026, Epistra Inc. CEO Yosuke Ozawa presented at the 10th Shonan iPark Regenerative Medicine Seminar, sharing implementation case studies and future prospects for AI and mathematical optimization in regenerative medicine process development.